Advertisement

Efficacy of allergen-blocker mechanical barrier gel on symptoms and quality of life in patients with allergic rhinitis

  • Seda Sirin KoseEmail author
  • Gizem Atakul
  • Suna Asilsoy
  • Ozkan Karaman
  • Nevin Uzuner
  • Ozden Anal
Rhinology
  • 54 Downloads

Abstract

Propose

Allergic rhinitis (AR) is a very common, chronic and global health problem. In the last two decades, the efficiency of barrier-enforcing measures in AR has been investigated. In this study, we aimed to evaluate the effect of allergen-blocker mechanical barrier gel (MBG) (AlerjiSTOP®) treatment on symptoms and quality of life score (QoLS) in patients with seasonal and perennial allergic rhinitis.

Methods

A single-center, prospective study was conducted between January 2017 and May 2018. Patients diagnosed with allergic rhinitis with a visual analogue scale (VAS) of 5 or higher (moderate/severe) were enrolled in the study. Patients were evaluated in terms of VAS, nasal symptom score (NSS), ocular symptom score (OSS), total symptom score (TSS) and QoLS at baseline, 1 week and 1 month of MBG treatment.

Results

A total of 83 patients with AR were enrolled in the study. Clinical and laboratory examinations showed that 50 (60.2%) patients were mono-sensitized. Allergen-blocker mechanical barrier gel treatment was performed as monotherapy in 22 (26.5%) patients. Median VAS, NSS, OSS and TSS decreased from 7 to 4, 8 to 3, 4 to 0 and 12 to 4, respectively (p < 0.0001). Correlation analysis revealed positive correlations between lower pediatric rhinoconjunctivitis quality of life questionnaire scores for patients under 12 years of age and decrease in VAS, NSS and TSS (r = 0.380, p = 0.008; r = 0.544, p < 0.0001; r = 0.543, p < 0.0001). Positive correlations were detected between lower rhinoconjunctivitis quality of life questionnaire (self-administered) scores for patients ≥ 12 years of age and decrease in VAS, NSS, OSS and TSS (r = 0.703, p < 0.0001; r = 0.465, p = 0.005; r = 0.526, p = 0.001; r = 0.624, p < 0.0001).

Conclusion

In conclusion, we found significant decrease in all symptom scores and improvement in QoLS of patients treated with MBG as monotherapy and combination therapy.

Keywords

Allergen-blocker mechanical barrier gel Allergic rhinitis Quality of life score Visual analogue scale Symptom score Pediatrics 

Notes

Acknowledgements

This study was presented as an oral presentation at the Pediatric Allergy and Asthma Meeting (PAAM) 2017 at London, United Kingdom, on October 26, 2017.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not for-profit sectors.

Compliance with ethical standards

Conflict of interest

The authors declare that there is no conflict of interest.

References

  1. 1.
    Bellanti JA, Wallerstedt DB (2000) Allergic rhinitis update: epidemiology and natural history. Allergy Asthma Proc 21:367–370CrossRefGoogle Scholar
  2. 2.
    Bellanti JA, Settipane RA (2012) The burden of allergic rhinitis on patients’ quality of life. Allergy Asthma Proc 33:112CrossRefGoogle Scholar
  3. 3.
    Benninger MS, Benninger RM (2009) The impact of allergic rhinitis on sexual activity, sleep, and fatigue. Allergy Asthma Proc 30:358–365CrossRefGoogle Scholar
  4. 4.
    Bousquet J, Neukirch F, Bousquet PJ et al (2006) Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol 117:158–162CrossRefGoogle Scholar
  5. 5.
    Meltzer EO, Blaiss MS, Naclerio RM et al (2012) Burden of allergic rhinitis: allergies in America, Latin America, and Asia-Pacific adult surveys. Allergy Asthma Proc 33:113–141CrossRefGoogle Scholar
  6. 6.
    Juniper EF (1997) Measuring health-related quality of life in rhinitis. J Allergy Clin Immunol 99:742–749CrossRefGoogle Scholar
  7. 7.
    Bousquet J, Khaltaev N et al (2008) World Health Organization; GA(2)LEN; AllerGen. allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 86:8–160CrossRefGoogle Scholar
  8. 8.
    Angier E, Willington J, Scadding G, S. et al (2010) Management of allergic and non-allergic rhinitis: a primary care summary of the BSACI guideline. Prim Care Respir J 19:217–222CrossRefGoogle Scholar
  9. 9.
    Josling P, Steadman S (2003) Use of cellulose powder for the treatment of seasonal allergic rhinitis. Adv Ther 20:213–219CrossRefGoogle Scholar
  10. 10.
    Emberlin JC, Lewis RA (2006) A double blind, placebo controlled trial of inert cellulose powder for the relief of symptoms of hay fever in adults. Curr Med Res Opin 22:275–285CrossRefGoogle Scholar
  11. 11.
    Cingi C, Unlu HH, Songu M et al (2010) Seawater gel in allergic rhinitis: entrapment effect and mucociliary clearance compared with saline. Ther Adv Respir Dis 4:13–18CrossRefGoogle Scholar
  12. 12.
    Böhm M, Avgitidou G, El Hassan E et al (2012) Liposomes: a new non-pharmacological therapy concept for seasonal-allergic-rhinoconjunctivitis. Eur Arch Otorhinolaryngol 269:495–502CrossRefGoogle Scholar
  13. 13.
    Eichel A, Bilstein A, Werkhäuser N et al (2014) Meta-analysis of the efficacy of ectoine nasal spray in patients with allergic rhinoconjunctivitis. J Allergy (Cairo) 2014:292545Google Scholar
  14. 14.
    Schwetz S, Olze H, Melchisedech S et al (2004) Efficacy of pollen blocker cream in the treatment of allergic rhinitis. Arch Otolaryngol Head Neck Surg 130:979–984CrossRefGoogle Scholar
  15. 15.
    Li Y, Wang D, Liu Q et al (2013) Randomized double-blind placebo-controlled crossover study of efficacy of pollen blocker cream for perennial allergic rhinitis. Am J Rhinol Allergy 27:299–303CrossRefGoogle Scholar
  16. 16.
    Åberg N, Ospanova ST, Nikitin NP et al (2014) A nasally applied cellulose powder in seasonal allergic rhinitis in adults with grass pollen allergy: a double-blind, randomized, placebo-controlled, parallel-group study. Int Arch Allergy Immunol 163:313–318CrossRefGoogle Scholar
  17. 17.
    Bousquet PJ, Combescure C, Neukirch F et al (2007) Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. Allergy 62:367–372CrossRefGoogle Scholar
  18. 18.
    Yüksel H, Yilmaz O, Söğüt A et al (2009) Validation and reliability study of the Turkish version of the Pediatric Rhinitis Quality of Life Questionnaire. Turk J Pediatr 51:361–366PubMedGoogle Scholar
  19. 19.
    Yuksel H, Yilmaz O, Alkan S et al (2009) Validity and reliability of Turkish version of rhinitis and mini-rhinitis quality of life questionnaires. Allergol Immunopathol (Madr) 37:293–297CrossRefGoogle Scholar
  20. 20.
    Valerieva A, Popov TA, Staevska M et al (2015) Effect of micronized cellulose powder on the efficacy of topical oxymetazoline in allergic rhinitis. Allergy Asthma Proc 36:134–139CrossRefGoogle Scholar
  21. 21.
    Åberg N, Dahl Å, Benson M (2011) A nasally applied cellulose powder in seasonal allergic rhinitis (SAR) in children and adolescents; reduction of symptoms and relation to pollen load. Pediatr Allergy Immunol 22:594–599CrossRefGoogle Scholar
  22. 22.
    Hoffman LR, Yen EH, Kanne JP et al (2005) Lipoid pneumonia due to Mexican folk remedies: cultural barriers to diagnosis. Arch Pediatr Adolesc Med 159:1043–1048CrossRefGoogle Scholar
  23. 23.
    Paz Lansberg M, DeTineo M, Lane J et al (2016) A clinical trial of a microcrystalline cellulose topical nasal spray on the acute response to allergen challenge. Am J Rhinol Allergy 30:269–273CrossRefGoogle Scholar
  24. 24.
    Braunstahl GJ (2009) United airways concept: what does it teach us about systemic inflammation in airways disease? Proc Am Thorac Soc 6:652–654CrossRefGoogle Scholar
  25. 25.
    Lightman S, Scadding GK (2012) Should intranasal corticosteroids be used for the treatment of ocular symptoms of allergic rhinoconjunctivitis? A review of their efficacy and safety profile. Int Arch Allergy Immunol 158:317–325CrossRefGoogle Scholar
  26. 26.
    Thompson AK, Juniper E, Meltzer EO (2000) Quality of life in patients with allergic rhinitis. Ann Allergy Asthma Immunol 85:338–348CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Pediatric Immunology and AllergyDokuz Eylul UniversityIzmirTurkey

Personalised recommendations